Cargando…

Effects of Shenmai injection combined with platinum-containing first-line chemotherapy on quality of life, immune function and prognosis of patients with nonsmall cell lung cancer: A protocol for systematic review and meta-analysis

BACKGROUND: Lung cancer is the leading cause of death among cancer patients worldwide. Close to 85% of lung cancer pathology types are nonsmall cell lung cancer (NSCLC). With advances in medicine, the survival rate of early-stage NSCLC has improved. Nevertheless, about 70% of patients are diagnosed...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yanqiong, Zhang, Chao, Pan, Cheng, Yang, Yunkui, Liu, Jin, Lv, Jialing, Pan, Guilin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8568423/
https://www.ncbi.nlm.nih.gov/pubmed/34871214
http://dx.doi.org/10.1097/MD.0000000000027524
_version_ 1784594435338665984
author Chen, Yanqiong
Zhang, Chao
Pan, Cheng
Yang, Yunkui
Liu, Jin
Lv, Jialing
Pan, Guilin
author_facet Chen, Yanqiong
Zhang, Chao
Pan, Cheng
Yang, Yunkui
Liu, Jin
Lv, Jialing
Pan, Guilin
author_sort Chen, Yanqiong
collection PubMed
description BACKGROUND: Lung cancer is the leading cause of death among cancer patients worldwide. Close to 85% of lung cancer pathology types are nonsmall cell lung cancer (NSCLC). With advances in medicine, the survival rate of early-stage NSCLC has improved. Nevertheless, about 70% of patients are diagnosed at an advanced stage, and chemotherapy is the primary treatment option. Chemotherapy causes toxic side effects such as bone marrow suppression, gastrointestinal reactions, and damage to vital organs, which are difficult for patients to tolerate. Many published literatures have reported that Shenmai injection (SMI) combined with platinum-containing first-line chemotherapy regimen for NSCLC can improve the recent efficacy, reduce toxic side effects and improve the quality of life. However, most of the studies were small samples and lacked persuasive power, while controversies existed among individual studies. Therefore, this study used meta-analysis to further evaluate the effects of SMI combined with platinum-containing first-line chemotherapy on the quality of life, immune function and prognosis of patients with NSCLC. METHODS: Wanfang, Chinese Biomedical Literature Database, Chinese National Knowledge Infrastructure, the Chongqing VIP Chinese Science and Technology Periodical Database, PubMed, Embase, and Web of Science databases were searched. The search was scheduled from the establishment of the database to September 2021. All randomized controlled trials comparing SMI in combination with platinum-containing first-line chemotherapy to platinum-containing first-line chemotherapy alone for the treatment of NSCLC were searched and evaluated for inclusion. Two investigators independently performed study selection, data extraction and synthesis. The Cochrane Risk of Bias tool was used to assess the risk of bias in the randomized controlled trials. Stata 16.0 software was used for meta-analysis. RESULTS: The results of this meta-analysis will be submitted to a peer-reviewed journal for publication. CONCLUSION: This study comprehensively evaluated the effects of SMI combined with platinum-containing first-line chemotherapy on quality of life, immune function and prognosis in patients with NSCLC to provide an evidence-based basis for clinical practice. ETHICS AND DISSEMINATION: The private information from individuals will not be published. This systematic review should also not damage participants’ rights. Ethical approval was not available. The results may be published in a peer-reviewed journal or disseminated in relevant conferences. OSF Registration number: DOI 10.17605/OSF.IO/AMKDC
format Online
Article
Text
id pubmed-8568423
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-85684232021-11-06 Effects of Shenmai injection combined with platinum-containing first-line chemotherapy on quality of life, immune function and prognosis of patients with nonsmall cell lung cancer: A protocol for systematic review and meta-analysis Chen, Yanqiong Zhang, Chao Pan, Cheng Yang, Yunkui Liu, Jin Lv, Jialing Pan, Guilin Medicine (Baltimore) 3800 BACKGROUND: Lung cancer is the leading cause of death among cancer patients worldwide. Close to 85% of lung cancer pathology types are nonsmall cell lung cancer (NSCLC). With advances in medicine, the survival rate of early-stage NSCLC has improved. Nevertheless, about 70% of patients are diagnosed at an advanced stage, and chemotherapy is the primary treatment option. Chemotherapy causes toxic side effects such as bone marrow suppression, gastrointestinal reactions, and damage to vital organs, which are difficult for patients to tolerate. Many published literatures have reported that Shenmai injection (SMI) combined with platinum-containing first-line chemotherapy regimen for NSCLC can improve the recent efficacy, reduce toxic side effects and improve the quality of life. However, most of the studies were small samples and lacked persuasive power, while controversies existed among individual studies. Therefore, this study used meta-analysis to further evaluate the effects of SMI combined with platinum-containing first-line chemotherapy on the quality of life, immune function and prognosis of patients with NSCLC. METHODS: Wanfang, Chinese Biomedical Literature Database, Chinese National Knowledge Infrastructure, the Chongqing VIP Chinese Science and Technology Periodical Database, PubMed, Embase, and Web of Science databases were searched. The search was scheduled from the establishment of the database to September 2021. All randomized controlled trials comparing SMI in combination with platinum-containing first-line chemotherapy to platinum-containing first-line chemotherapy alone for the treatment of NSCLC were searched and evaluated for inclusion. Two investigators independently performed study selection, data extraction and synthesis. The Cochrane Risk of Bias tool was used to assess the risk of bias in the randomized controlled trials. Stata 16.0 software was used for meta-analysis. RESULTS: The results of this meta-analysis will be submitted to a peer-reviewed journal for publication. CONCLUSION: This study comprehensively evaluated the effects of SMI combined with platinum-containing first-line chemotherapy on quality of life, immune function and prognosis in patients with NSCLC to provide an evidence-based basis for clinical practice. ETHICS AND DISSEMINATION: The private information from individuals will not be published. This systematic review should also not damage participants’ rights. Ethical approval was not available. The results may be published in a peer-reviewed journal or disseminated in relevant conferences. OSF Registration number: DOI 10.17605/OSF.IO/AMKDC Lippincott Williams & Wilkins 2021-11-05 /pmc/articles/PMC8568423/ /pubmed/34871214 http://dx.doi.org/10.1097/MD.0000000000027524 Text en Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/)
spellingShingle 3800
Chen, Yanqiong
Zhang, Chao
Pan, Cheng
Yang, Yunkui
Liu, Jin
Lv, Jialing
Pan, Guilin
Effects of Shenmai injection combined with platinum-containing first-line chemotherapy on quality of life, immune function and prognosis of patients with nonsmall cell lung cancer: A protocol for systematic review and meta-analysis
title Effects of Shenmai injection combined with platinum-containing first-line chemotherapy on quality of life, immune function and prognosis of patients with nonsmall cell lung cancer: A protocol for systematic review and meta-analysis
title_full Effects of Shenmai injection combined with platinum-containing first-line chemotherapy on quality of life, immune function and prognosis of patients with nonsmall cell lung cancer: A protocol for systematic review and meta-analysis
title_fullStr Effects of Shenmai injection combined with platinum-containing first-line chemotherapy on quality of life, immune function and prognosis of patients with nonsmall cell lung cancer: A protocol for systematic review and meta-analysis
title_full_unstemmed Effects of Shenmai injection combined with platinum-containing first-line chemotherapy on quality of life, immune function and prognosis of patients with nonsmall cell lung cancer: A protocol for systematic review and meta-analysis
title_short Effects of Shenmai injection combined with platinum-containing first-line chemotherapy on quality of life, immune function and prognosis of patients with nonsmall cell lung cancer: A protocol for systematic review and meta-analysis
title_sort effects of shenmai injection combined with platinum-containing first-line chemotherapy on quality of life, immune function and prognosis of patients with nonsmall cell lung cancer: a protocol for systematic review and meta-analysis
topic 3800
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8568423/
https://www.ncbi.nlm.nih.gov/pubmed/34871214
http://dx.doi.org/10.1097/MD.0000000000027524
work_keys_str_mv AT chenyanqiong effectsofshenmaiinjectioncombinedwithplatinumcontainingfirstlinechemotherapyonqualityoflifeimmunefunctionandprognosisofpatientswithnonsmallcelllungcanceraprotocolforsystematicreviewandmetaanalysis
AT zhangchao effectsofshenmaiinjectioncombinedwithplatinumcontainingfirstlinechemotherapyonqualityoflifeimmunefunctionandprognosisofpatientswithnonsmallcelllungcanceraprotocolforsystematicreviewandmetaanalysis
AT pancheng effectsofshenmaiinjectioncombinedwithplatinumcontainingfirstlinechemotherapyonqualityoflifeimmunefunctionandprognosisofpatientswithnonsmallcelllungcanceraprotocolforsystematicreviewandmetaanalysis
AT yangyunkui effectsofshenmaiinjectioncombinedwithplatinumcontainingfirstlinechemotherapyonqualityoflifeimmunefunctionandprognosisofpatientswithnonsmallcelllungcanceraprotocolforsystematicreviewandmetaanalysis
AT liujin effectsofshenmaiinjectioncombinedwithplatinumcontainingfirstlinechemotherapyonqualityoflifeimmunefunctionandprognosisofpatientswithnonsmallcelllungcanceraprotocolforsystematicreviewandmetaanalysis
AT lvjialing effectsofshenmaiinjectioncombinedwithplatinumcontainingfirstlinechemotherapyonqualityoflifeimmunefunctionandprognosisofpatientswithnonsmallcelllungcanceraprotocolforsystematicreviewandmetaanalysis
AT panguilin effectsofshenmaiinjectioncombinedwithplatinumcontainingfirstlinechemotherapyonqualityoflifeimmunefunctionandprognosisofpatientswithnonsmallcelllungcanceraprotocolforsystematicreviewandmetaanalysis